IPO News | Qinhao Pharmaceutical's Hong Kong Stock IPO Prospectus Expires

Zhitongcaijing · 1d ago

The Zhitong Finance App learned that the Hong Kong Stock Prospectus submitted by Qinhao Pharmaceutical (Suzhou) Co., Ltd. (abbreviation: Qinhao Pharmaceutical) on January 16, 2026 expired for 6 months on July 16, 2026, and Huatai International is its sole sponsor.

WeChat photo_20260716060936_9225_14.png

According to the previous prospectus, Qin Hao Pharmaceutical is a biopharmaceutical company that mainly focuses on developing potentially best-in-class targeted therapies in the field of oncology. We have a differentiated and powerful independent development and innovative drug candidate pipeline built around the RAS signaling pathway and synthetic lethal mechanism. According to Insight Consulting data, the company's multiple drug candidates are in a leading position in the world in terms of clinical progress with the same target.

The company's core product, GH21, is a potentially best-in-class variant SHP2 inhibitor and is currently in phase 2 clinical trials. The company obtained IND approval from the State Drug Administration for treating advanced solid tumors with GH21 monotherapy in November 2021, began its phase 1 single-agent clinical trial in May 2022, and obtained a clinical study report in March 2025 to complete the phase 1 clinical trial.